Cytosorbents Corp (CTSO)
CIK 1175151 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 62.8M shares as of Jul 31, 2026 (10-Q). Share count fell from 581.8M to 24.6M between Nov 7, 2014 and Mar 23, 2015, a pattern consistent with a reverse split (roughly 1-for-24); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series Right Offering | 6.3M | not tagged | — | — |
| Seriesa Right Warrants | 4.8M | $1.13 | — | — |
| December132023 Offering | 2.7M | $2 | — | — |
| Warrant One | 1.6M | $0.79 | — | FV $690,000 |
| Warrant Two | 1.4M | $0.7 | — | FV $627,000 |
| Series B Right Warrants | not tagged | $2 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 5.8M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $1.13 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $1.0M as of Jun 30, 2017.
Rough fully diluted estimate: 68.6M = 62.8M O/S + 5.8M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Loan and Security Agreement | not tagged | $17.5M | $0.95 | — | — |
Notes exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 62.8M | Jul 31, 2026 |
| + Series Right Offering (if exercised) | 6.3M | Jan 10, 2025 |
| + Seriesa Right Warrants (if exercised) | 4.8M | Feb 24, 2025 |
| + December132023 Offering (if exercised) | 2.7M | Dec 13, 2023 |
| + Warrant One (if exercised) | 1.6M | Jun 28, 2024 |
| + Warrant Two (if exercised) | 1.4M | Nov 13, 2025 |
| Fully diluted estimate | 79.7M | +26.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 0 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full CTSO workspace